You are here

  • Home
  • Archive
  • Volume 10, Issue 9
  • GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

Article info

Article menu
Immune cell therapies and immune cell engineering
Original research
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

Authors

  • Tessa Gargett Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and Univeristy of South Australia, Adelaide, South Australia, AustraliaCancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, AustraliaAdelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Lisa M Ebert Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and Univeristy of South Australia, Adelaide, South Australia, AustraliaAdelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Nga T H Truong Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and Univeristy of South Australia, Adelaide, South Australia, AustraliaCancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Paris M Kollis Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and Univeristy of South Australia, Adelaide, South Australia, AustraliaAdelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Kristyna Sedivakova Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and Univeristy of South Australia, Adelaide, South Australia, AustraliaAdelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Wenbo Yu Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and Univeristy of South Australia, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Erica C F Yeo Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and Univeristy of South Australia, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Nicole L Wittwer Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and Univeristy of South Australia, Adelaide, South Australia, AustraliaCancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Briony L Gliddon Molecular Therapeutics Laboratory, Centre for Cancer Biology, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Melinda N Tea Molecular Therapeutics Laboratory, Centre for Cancer Biology, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Rebecca Ormsby Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Santosh Poonnoose Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, AustraliaDepartment of Neurosurgery, Flinders Medical Centre, Bedford Park, South Australia, Australia PubMed articlesGoogle scholar articles
  • Jake Nowicki Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, AustraliaDepartment of Neurosurgery, Flinders Medical Centre, Bedford Park, South Australia, Australia PubMed articlesGoogle scholar articles
  • Orazio Vittorio Children's Cancer Institute, Lowy Cancer Research Centre, Sydney, New South Wales, AustraliaSchool of Women's and Children's Health, University of New South Wales, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • David S Ziegler Children's Cancer Institute, Lowy Cancer Research Centre, Sydney, New South Wales, AustraliaSchool of Women's and Children's Health, University of New South Wales, Sydney, New South Wales, AustraliaKid's Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia PubMed articlesGoogle scholar articles
  • Stuart M Pitson Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, AustraliaMolecular Therapeutics Laboratory, Centre for Cancer Biology, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Michael P Brown Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and Univeristy of South Australia, Adelaide, South Australia, AustraliaCancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, AustraliaAdelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Tessa Gargett; tessa.gargett{at}sa.gov.au
View Full Text

Citation

Gargett T, Ebert LM, Truong NTH, et al
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma
Journal for ImmunoTherapy of Cancer 2022;10:e005187. doi: 10.1136/jitc-2022-005187

Publication history

  • Accepted September 13, 2022
  • First published September 27, 2022.
Online issue publication 
September 27, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.